Prices delayed by at least 15 minutes | Print
Gilead Sciences (GILD)
Common SharesOpen
$67.47
Previous close
$67.08
Trade high
$67.9
Volume
15,171,959
Year high
$87.87
Year low
$65.09
Dividend yield
4.5%
Market capitalisation
$81.39 bn
P/E ratio
14.91
ISIN
US3755581036
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Dividends
Previous | Latest | |
---|---|---|
Record date | 15/12/2023 | 15/03/2024 |
Ex-dividend date | 14/12/2023 | 14/03/2024 |
Payment date | 28/12/2023 | 28/03/2024 |
Amount | $0.75 | $0.77 |
Company profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.